Skip to main content
Figure 2 | BMC Nephrology

Figure 2

From: Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Figure 2

Peptide patterns of 273 CKD marker used for the proteomic analysis of patients from the 'IRMA2' subgroup. The compiled data sets of urine samples from patients derived from the 'IRMA2 study' before and after 2-year treatment of Irbesartan (upper panel) as well as placebo (lower panel) are shown. Normalized molecular mass (y-axis) is plotted against normalized CE-migration time (x-axis). The mean signal intensity is represented in 3D-depiction.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us